0001209191-21-005158.txt : 20210125 0001209191-21-005158.hdr.sgml : 20210125 20210125174108 ACCESSION NUMBER: 0001209191-21-005158 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210121 FILED AS OF DATE: 20210125 DATE AS OF CHANGE: 20210125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carter Martha J. CENTRAL INDEX KEY: 0001213040 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 21550967 MAIL ADDRESS: STREET 1: C/O AEGERION PHARMACEUTICALS, INC. STREET 2: 89 HEADQUARTERS PLAZA, SUITE 1212 CITY: MORRISTOWN STATE: NJ ZIP: 07960 FORMER NAME: FORMER CONFORMED NAME: CARTER MARTHA J DATE OF NAME CHANGE: 20030106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-21 0 0001322505 ALBIREO PHARMA, INC. ALBO 0001213040 Carter Martha J. C/O ALBIREO PHARMA, INC. 10 POST OFFICE SQUARE, SUITE 1000 BOSTON MA 02109 0 1 0 0 Chief Regulatory Officer Common Stock 2021-01-21 4 A 0 5500 0.00 A 5500 D Stock Option (right to buy) 34.88 2021-01-21 4 A 0 23700 0.00 A 2031-01-20 Common Stock 23700 23700 D Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. Represents 5,500 restricted stock units. This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. /s/ Jason Duncan, Attorney-in-fact 2021-01-25